Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994796 · ClinicalTrials.gov registry record · Phase 2
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03994796 is a Phase 2 study that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 50 participants.
The verdict
NCT03994796, a Phase 2 study, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
Interventions
- DRUG Abemaciclib
- DRUG Adagrasib
- DRUG Entrectinib
- DRUG PI3K Inhibitor paxalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03994796
The ClinicalTrials.gov registry entry for NCT03994796 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abemaciclib is the first listed.
NCT03994796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03994796 about?
NCT03994796 is a clinical study titled "Genetic Testing in Guiding Treatment for Patients With Brain Metastases". This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes su...
What is the current status of trial NCT03994796?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2019-10-17. Estimated completion is 2028-06.
What interventions are being tested in trial NCT03994796?
The interventions under investigation include: Abemaciclib (DRUG), Adagrasib (DRUG), Entrectinib (DRUG), PI3K Inhibitor paxalisib (DRUG).
Who is sponsoring clinical trial NCT03994796?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.